Figure 5. SUMF1 overexpression is significantly correlated with cancer progression in subgroups of patients with glioma. (A) IDH mutant patients; (B) The patients with the non-codel in 1p/19q codeletion; (C) Female; (D) Male; (E) Age ≤60; (F) Age >60; (G) Astrocytoma; (H) Oligodendroglioma.